Free Trial

International Assets Investment Management LLC Has $666,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics logo with Medical background

International Assets Investment Management LLC boosted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 50.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,584 shares of the biotechnology company's stock after purchasing an additional 9,308 shares during the quarter. International Assets Investment Management LLC's holdings in Viking Therapeutics were worth $666,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Parallel Advisors LLC raised its stake in shares of Viking Therapeutics by 64.8% in the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after buying an additional 536 shares in the last quarter. FIL Ltd raised its stake in shares of Viking Therapeutics by 116.8% in the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after buying an additional 648 shares in the last quarter. NBC Securities Inc. raised its stake in shares of Viking Therapeutics by 222,100.0% in the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,221 shares in the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of Viking Therapeutics by 170.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock valued at $55,000 after buying an additional 851 shares in the last quarter. Finally, Future Financial Wealth Managment LLC raised its stake in shares of Viking Therapeutics by 1,242.9% in the 1st quarter. Future Financial Wealth Managment LLC now owns 2,350 shares of the biotechnology company's stock valued at $57,000 after buying an additional 2,175 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VKTX has been the subject of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Wednesday. Cantor Fitzgerald upgraded shares of Viking Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 29th. The Goldman Sachs Group initiated coverage on shares of Viking Therapeutics in a research report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 target price for the company. Morgan Stanley dropped their target price on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Finally, Truist Financial reiterated a "buy" rating and set a $75.00 target price (down previously from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Viking Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $87.15.

View Our Latest Stock Analysis on Viking Therapeutics

Viking Therapeutics Stock Down 5.9%

NASDAQ:VKTX traded down $1.65 during mid-day trading on Friday, reaching $26.52. 6,315,541 shares of the company were exchanged, compared to its average volume of 4,023,381. Viking Therapeutics, Inc. has a 12 month low of $18.92 and a 12 month high of $81.73. The company has a fifty day moving average of $27.19 and a 200 day moving average of $30.21. The stock has a market cap of $2.98 billion, a PE ratio of -23.06 and a beta of 0.65.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The company's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.26) EPS. On average, equities research analysts anticipate that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Insider Activity

In other Viking Therapeutics news, Director Sarah Kathryn Rouan bought 1,240 shares of Viking Therapeutics stock in a transaction dated Monday, March 31st. The shares were bought at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now owns 1,240 shares of the company's stock, valued at $29,946. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.10% of the company's stock.

About Viking Therapeutics

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

See Also

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Should You Invest $1,000 in Viking Therapeutics Right Now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines